Case Report | Open Access
Sarah Bouri, Jean-Christophe Noël, Xavier Catteau, Walid Al Hajj Obeid, Ilyas Svistakov, Thierry Roumeguère, Nicky D’Haene, Sandrine Rorive, "KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature", Case Reports in Urology, vol. 2020, Article ID 5419707, 4 pages, 2020. https://doi.org/10.1155/2020/5419707
KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
Ovarian-like epithelial tumors of the testis, including serous borderline tumors, are rare entities. We report the case of a 60-year-old man with a left intratesticular mass who had a radical orchidectomy. Histologically, the tumor was identical to the ovarian counterpart showing a well-delineated cystic lesion characterized by intraluminal papillae. The papillae are lined by atypical cuboidal or ciliated cells and are associated with psammoma bodies. The tumor cells express cytokeratin 7 (CK7), cytokeratin 5-6 (CK5-6), cancer antigen 125 (CA125), estrogen (ER), progesterone (PR), Wilm’s tumor gene (WT1), paired box gene 8 (PAX8), Ber-EP4, and epithelial membrane antigen (EMA). The diagnosis of a serous borderline tumor of the testis was proposed. Mutation testing using next-generation sequencing showed a Q61K KRAS gene mutation. To the best of our knowledge, this is the second case report of a serous borderline tumor of the testis with a Q61K KRAS gene mutation.
Ovarian Mullerian-like epithelial tumors of the testis are exceedingly rare tumors with about 50 cases described in the literature [1–5]. Like in the ovarian counterpart, serous, mucinous, clear cell, and seromucinous carcinomas have been previously reported [6–8]. The mutational molecular profile of these tumors is poorly understood with only 5 previous cases well documented. In particular, in the serous tumor of the testis, only one previous article had suggested that like in the ovarian neoplasms, KRAS mutation could play a role in the development of these tumors . Here, we report the second case of a serous borderline tumor of the testis in which a mutation of the Q61K KRAS gene is demonstrated. Our data were analysed in the highlight of the literature concerning the molecular profile of this unusual neoplasm.
2. Case Presentation
A 60-year-old man was referred to the urological consultation of Erasme University Hospital for a left intratesticular mass felt by the patient for about six months. At the ultrasound, this tumor of approximately mm was heterogenous and hypoechogenic and contained calcifications (Figure 1).
The epididymis and right testis were normal. Testicular cancer tumor markers such as human chorionic gonadotropin (hCG), alpha-foetoprotein (AFP), and lactate dehydrogenase (LDH) were within normal limits. Therefore, a left radical orchidectomy was performed. Macroscopic examination revealed an intratesticular heterogenous cystic lesion measuring mm and containing an endoluminal whitish area (Figure 2).
Microscopically, the tumor was well delineated and characterized by intraluminal papillae. The papillae are lined by pseudo- or pluristratified atypical cuboidal and/or ciliated epithelium. The mitotic index is less than 5 mitoses per HPF (×400). Rare psammoma bodies are also observed. No capsular invasion or vascular involvement is noted (Figure 3).
The tumor cells express cytokeratin-7 (CK7 clone OV/TL12/30, 1 : 400, Leica Newcastle, United Kingdom), cytokeratin 5-6 (CK 5-6 clone D 5/6 B4, 1 : 100, Dako, Glostrup, Denmark), cancer antigen 125 (CA-125 clone M1, ready to use, Dako, Glostrup, Denmark), estrogen (ER clone EP1, 1 : 50, Dako, Glostrup, Denmark), progesterone (PR clone 16+SAN27, 1 : 500, Leica Newcastle, United Kingdom), Wilm’s tumor gene (WT1 clone 6F-H2, 1 : 150, Dako, Glostrup, Denmark), paired box gene 8 (PAX8 clone MRQ-50, ready to use, Menarini, Firenze, Italy), Ber-EP4 (clone Ber-EP4, 1 : 800, Dako, Glostrup, Denmark), and epithelial membrane antigen (EMA clone E29, 1 : 400, Dako, Glostrup Denmark). We do not observe immunopositivity for cytokeratin 20 (CK20 clone Ks 20.8, 1 : 100, Dako, Glostrup, Denmark), CDX2 gene (clone DAK-CDX2, 1 : 100, Dako, Glostrup, Denmark), Sal-like protein 4 (SALL4, clone 6E3, 1 : 100, Cell-Marque, California, United States), human chorionic gonadotropin (beta-HCG clone GA508, ready to use, Dako, Glostrup, Denmark), alpha-foetoprotein (AFP clone GA500, ready to use, Dako, Glostrup, Denmark), podoplanin (clone D2-40, ready to use, Dako, Glostrup, Denmark), and calretinin (clone DAK Calret 1, 1 : 300, Dako, Glostrup, Denmark). p53 protein (clone DO-7, 1 : 200, Dako, Glostrup, Denmark) expression is weak and patchy. The proliferative index evaluated by Ki-67 antibody (clone MIB-1, 1 : 200, Dako, Glostrup, Denmark) is about 10%.
The molecular profile of the lesion was performed using next-generation sequencing (NGS) with a panel of 16 genes, described in Table 1 . Briefly, DNA was isolated from formalin-fixed and paraffin-embedded (FFPE) tumor samples using the QIAamp FFPE tissue kit (Qiagen, Antwerp, Belgium), according to the manufacturer’s instructions. First of all, tumor tissue was manually microdissected with a scalpel on a 10 μm paraffin slide using the H&E-stained slide cut from the same block. This H&E-stained slide was previously reviewed by a pathologist to evaluate the tumor cell percentage in the tumor area. DNA was then quantified using the Qubit® fluorometer and Qubit® ds DNA HS assay kit (Life Technologies, Gent, Belgium). Detection of mutations was performed using a next-generation platform (Ion Torrent, Life Technologies) with a panel of 16 genes (Table 1) previously validated at the Department of Pathology at Erasme Hospital (Brussels, Belgium) [10, 11]. The mutational analysis revealed a Q61K KRAS gene mutation in the testicular tumor.
Ovarian-like epithelial tumors of the testis are extremely rare [1–5]. All types of epithelial tumors, serous, mucinous, seromucinous, and clear cell tumors, have been reported in the testis [6–8]. The most frequently reported types are serous borderline tumors, which share histological and immunohistological similarities with their ovarian counterpart.
These similarities found in such ovarian and testicular serous neoplasms can provide a better comprehension of the pathogenesis of serous borderline testis tumors.
Indeed, several hypotheses are proposed ; these tumors may arise from (1) embryological Mullerian remnants in paratesticular tissue, spermatic cord, or epididymis or (2) Mullerian metaplasia of intratesticular inclusions of the tunica vaginalis. This second hypothesis shows a similarity with the origin of the development of the ovarian counterpart, which seems to grow from germinal surface epithelium .
We report here a case of a serous borderline tumor of the testis showing a Q61K KRAS gene mutation. This is the second reported case of a KRAS gene mutation in this type of testis tumor. The other gene mutations in these tumors include BRAF gene mutations (Table 2) [9, 12, 14].
Interestingly, in ovarian serous borderline neoplasms, BRAF and KRAS gene mutations are frequently found and known to be involved in the carcinogenesis of these tumors and support common pathogenesis in serous borderline tumors of both female and male, possibly arising from Mullerian origin/remnants [15–17]. BRAF and KRAS are protooncogenes involved in the mitogen-activated protein kinase (MAPK) pathway. The activation of this pathway involves the cascade of activation of signaling proteins such as RAS, RAF, MEK, and ERK, which leads to increased cell growth and differentiation. Mutations in BRAF or KRAS gene result in the constitutional activation of the MAPK pathway and aberrant cell proliferation [18, 19].
Low-grade serous lesions of the testis and their ovarian counterpart have the potentiality of recurrence and metastasis after surgery [20, 21]. Classically, this kind of tumors has shown a low response rate to cytotoxic chemotherapy [20–22]. Therefore, the RAS/RAF/MEK/ERK pathway could constitute an attractive target for cancer drugs in patients with KRAS and/or BRAF mutations .
Naturally, due to the rarity of these tumors in testis, their mutational status should be confirmed in the future in a larger series.
Conflicts of Interest
The authors declare that they have no conflict of interest regarding the publication of this article.
- A. S. Ibrahim, C. Li, and M. S. al-Jafari, “Borderline serous papillary tumour of the testis: a case report and review of the literature,” Anticancer Research, vol. 32, no. 11, pp. 5011–5013, 2012.
- H. Maruyama, N. Ohyama, Y. Hosokawa et al., “Serous borderline tumor of the paratestis,” Pathology International, vol. 58, no. 5, pp. 311–316, 2008.
- L. S. Abdullah, R. Gupta, and A. Arnst, “Intratesticular borderline serous tumor,” International Journal of Urology, vol. 13, no. 12, pp. 1536–1538, 2006.
- R. F. McClure, G. L. Keeney, T. J. Sebo, and J. C. Cheville, “Serous borderline tumor of the paratestis: a report of seven cases,” The American Journal of Surgical Pathology, vol. 25, no. 3, pp. 373–378, 2001.
- R. Guarch, A. Rivas, A. Puras, and C. Pesce, “Papillary serous carcinoma of ovarian type of the testis with borderline differentiation,” Histopathology, vol. 46, no. 5, pp. 588–590, 2005.
- A. Z. Thomas, T. E. D. McDermott, S. Crowther, and J. A. Thornhill, “Primary clear cell carcinoma of the rete testis: 1st report,” Case Reports, vol. 2015, 2015.
- B. Scholz, M. Beckert, V. Mordstein, N. Hohmann, R. Walther, and T. Papadopoulos, “Seromucinous borderline tumor of the testis—a case report,” Human Pathology, vol. 60, pp. 188–191, 2017.
- S. Menon, S. Desai, and S. Ahmed, “Primary borderline mucinous neoplasm of the testis: a case report and literature review,” Indian Journal of Urology, vol. 28, no. 2, pp. 224–226, 2012.
- P. Gwiti, I. Vereczkey, D. Cundell et al., “The mutational frequency ofBRAFandKRASin low-grade serous testicular neoplasms-a case series,” Histopathology, vol. 71, no. 5, pp. 686–692, 2017.
- L. Bienfait, N. D’Haene, X. Catteau, and J. C. Noël, “PIK3CA and p53 mutations by next generation sequencing in lymphoepithelioma-like carcinoma of the endometrium,” Case Reports in Pathology, vol. 2018, Article ID 5894589, 5 pages, 2018.
- C. Koopmansch, C. Maris, P. Demetter et al., “Differentiated-type intraepithelial neoplasia-like lesion associated with squamous cell carcinoma of the anus: a case report with molecular profile,” Case Reports in Pathology, vol. 2019, Article ID 2301640, 5 pages, 2019.
- T. Bürger, H.-U. Schildhaus, R. Inniger et al., “Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis,” Diagnostic Pathology, vol. 10, no. 1, p. 118, 2015.
- M. Michal, D. V. Kazakov, D. Kacerovska et al., “Paratesticular cystadenomas with ovarian stroma, metaplastic serous Müllerian epithelium, and male adnexal tumor of probable Wolffian origin: a series of 5 hitherto poorly recognized testicular tumors,” Annals of Diagnostic Pathology, vol. 17, no. 2, pp. 151–158, 2013.
- D. Cundell, J. Pawade, M. Sohail, and Z. Melegh, “The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart,” Histopathology, vol. 67, no. 1, pp. 142–144, 2015.
- I. M. Shih and R. J. Kurman, “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis,” The American Journal of Pathology, vol. 164, no. 5, pp. 1511–1518, 2004.
- D. Mayr, A. Hirschmann, U. Löhrs, and J. Diebold, “KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants,” Gynecologic Oncology, vol. 103, no. 3, pp. 883–887, 2006.
- G. Singer, R. Oldt, Y. Cohen et al., “Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 6, pp. 484–486, 2003.
- M. Burotto, V. L. Chiou, J. M. Lee, and E. C. Kohn, “The MAPK pathway across different malignancies: a new perspective,” Cancer, vol. 120, no. 22, pp. 3446–3456, 2014.
- P. T. C. Wan, M. J. Garnett, S. M. Roe et al., “Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF,” Cell, vol. 116, no. 6, pp. 855–867, 2004.
- M. A. Jones, R. H. Young, J. R. Srigley, and R. E. Scully, “Paratesticular serous papillary carcinoma a report of six cases,” The American Journal of Surgical Pathology, vol. 19, no. 12, pp. 1359–1365, 1995.
- Y. T. Ma, S. Chaudhri, and M. H. Cullen, “Metastatic serous carcinoma of the testis: a case report and review of the literature,” Case Reports in Oncology, vol. 4, no. 1, pp. 246–249, 2011.
- C.-H. Yeh, P.-P. Hsieh, S.-J. Lin et al., “Testicular serous carcinoma of ovarian epithelial type,” Journal of Cancer Research and Practice, vol. 4, no. 2, pp. 76–79, 2017.
- P. J. Roberts and C. J. Der, “Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer,” Oncogene, vol. 26, no. 22, pp. 3291–3310, 2007.
Copyright © 2020 Sarah Bouri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.